The Proposed TRIPS Waiver and Pharmaceutical Industry’s Concerns about Counterfeit COVID-19 Vaccines

[Muhammad Zaheer Abbas] Submission to the Australian Parliament’s Joint Committee on Law Enforcement Inquiry into Vaccine Related Fraud and Security Risks - Executive Summary: Australia needs to support the proposal of temporarily waiving intellectual property protections to scale up production and supply of vaccines and other COVID-19 related treatments and diagnostics. The Brand-name pharmaceutical industry’s claim that the proposed TRIPS waiver will result in the proliferation of counterfeit vaccines and treatments is not supported by empirical evidence.